A post hoc analysis of the SUSTAIN 6 trial found semaglutide reduced the odds of developing diabetic kidney disease by 44% overall and 49% in high-risk patients, with a number needed to treat of just 7 in the high-risk group.
NNT = 7in high-risk patients — meaning only 7 patients need semaglutide treatment to prevent one new case of diabetic kidney disease, an exceptionally effective prevention ratio
What the researchers found
Semaglutide reduced the odds of developing new diabetic kidney disease by 44% overall (OR 0.56, p<0.0001) and 49% in high-risk patients (OR 0.51), with NNT of 7 in the high-risk population, primarily by reducing urinary albumin excretion.
Why it matters
Diabetic kidney disease leads to dialysis for millions of people worldwide and is the leading cause of kidney failure. Finding that semaglutide — already widely prescribed for diabetes and weight loss — can nearly halve the risk of developing DKD means a drug many patients are already taking could protect their kidneys too, potentially preventing years of dialysis.
The numbers in context
SUSTAIN 6 participants classified by DKD risk model; semaglutide vs. placebo for primary DKD prevention.
How the study worked
Post hoc analysis of the SUSTAIN 6 randomized, double-blind, placebo-controlled trial. Included 1,139 participants with T2D without DKD at baseline. Stratified by validated DKD risk model. Primary outcome: development of DKD (UACR ≥30 mg/g and/or eGFR decline). Compared semaglutide 0.5/1.0 mg vs. placebo.
Who was studied
Type 2 diabetes patients at high risk for diabetic kidney disease in SUSTAIN 6
What this study cannot tell us
Post hoc analysis — not a pre-specified trial endpoint, so results need confirmation in prospective studies. The DKD risk model classification may not capture all relevant patient differences. SUSTAIN 6 was not designed or powered to assess DKD prevention specifically. The analysis doesn't distinguish between semaglutide's direct kidney effects and indirect effects through blood sugar and weight reduction.
How to read the evidence
Strong with caveats — based on a well-designed RCT (SUSTAIN 6) with 1,139 participants, but this is a post hoc analysis, not a pre-specified endpoint. Results are highly statistically significant but need prospective confirmation.
When this study was published
Published in 2024, analyzing data from SUSTAIN 6 (completed 2016). The risk model and DKD prevention analysis are new contributions.
The bigger picture
This finding adds kidney protection to semaglutide's growing list of benefits beyond blood sugar control, joining cardiovascular risk reduction and weight loss. If confirmed in prospective trials, semaglutide could become a cornerstone of DKD prevention — particularly significant since GLP-1 agonists are increasingly prescribed as first-line diabetes treatments. The NNT of 7 makes a powerful case for early intervention in high-risk patients.
Questions still open
- Is semaglutide's kidney protection a direct effect on renal tissue or an indirect result of improved blood sugar and weight?
- Would earlier initiation of semaglutide in newly diagnosed T2D provide even greater DKD prevention?
- Do oral semaglutide formulations provide the same kidney-protective benefits as injectable?
Common questions
Could semaglutide prevent kidney disease in people with diabetes?
How does semaglutide protect the kidneys?
Read the original research
Effect of semaglutide on primary prevention of diabetic kidney disease in people with type 2 diabetes: A post hoc analysis of the SUSTAIN 6 randomized controlled trial.
Diabetes, obesity & metabolism, 26(11), 5157-5166
Citation
Wang, Jingyu; Yang, Juhong; Jiang, Wenhui; Liu, Wenyan; Shen, Zewei; Gao, Zhongai; Chang, Baocheng. (2024). Effect of semaglutide on primary prevention of diabetic kidney disease in people with type 2 diabetes: A post hoc analysis of the SUSTAIN 6 randomized controlled trial.. Diabetes, obesity & metabolism, 26(11), 5157-5166. https://doi.org/10.1111/dom.15860